Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.57 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.49 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16804878 | 1.00 | PARP1 (0.57) | PARP1PDE3BPDE3ASMYD3TP53 | |
| SCHEMBL6995045 | 0.81 | PARP1 (0.50) | PARP1PDE3BPDE3ASMYD3MAOB | |
| SCHEMBL6994127 | 0.81 | PARP1 (0.50) | PARP1PDE3BPDE3ASMYD3HSD17B10 | |
| SCHEMBL5670717 | 0.79 | PARP1 (0.62) | PARP1PDE3BPDE3ASMYD3BRD4 | |
| SCHEMBL10130302 | 0.79 | PARP1 (0.62) | PARP1PDE3BPDE3ASMYD3BRD4 | |
| SCHEMBL10130365 | 0.79 | PARP1 (0.62) | PARP1PDE3BPDE3ASMYD3BRD4 | |
| SCHEMBL8194602 | 0.78 | PARP1 (0.61) | PARP1PDE3BPDE3ASMYD3MAPT | |
| SCHEMBL2917545 | 0.78 | PARP1 (0.60) | PARP1PDE3BPDE3ASMYD3MAOB | |
| SCHEMBL292432 | 0.78 | PARP1 (0.60) | PARP1PDE3BPDE3ASMYD3MAOB | |
| SCHEMBL5670852 | 0.78 | PARP1 (0.60) | PARP1PDE3BPDE3ASMYD3TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230554-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-10259826-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180072756-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230554-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | SSB, TPMT, ADAR | PARP1 464/4885PDE3B 561/4885PDE3A 622/4885 |
| US-10259826-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | SSB, TPMT, ADAR | PARP1 464/4885PDE3B 561/4885PDE3A 622/4885 |
| US-20180072756-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | SSB, TPMT, ADAR | PARP1 464/4885PDE3B 561/4885PDE3A 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.